A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.

Date publication

décembre 2022

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel , Pr PETIT Thierry , Pr PIVOT Xavier , Dr DEMARCHI Martin , Dr COLIAT Pierre , Dr BENDER Laura

Tous les auteurs :
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36562910

Résumé

A 4-weekly schedule of pegylated liposomal doxorubicin (PLD) has been approved for the treatment of metastatic breast cancer (MBC). Phase II trials have suggested interest in a 2-weekly regimen. This study aimed to compare the efficacy and safety of these two schedules.

Mots clés

Anthracyclines, Metastatic breast cancer, Pegylated liposomal doxorubicin, Propensity score, Schedule

Référence

Breast Cancer Res Treat. 2022 12 23;: